JP2023540436A - Ｐｄ－ｌ１およびｔｇｆ－βを標的とする二機能性分子 - Google Patents

Ｐｄ－ｌ１およびｔｇｆ－βを標的とする二機能性分子 Download PDF

Info

Publication number
JP2023540436A
JP2023540436A JP2023505901A JP2023505901A JP2023540436A JP 2023540436 A JP2023540436 A JP 2023540436A JP 2023505901 A JP2023505901 A JP 2023505901A JP 2023505901 A JP2023505901 A JP 2023505901A JP 2023540436 A JP2023540436 A JP 2023540436A
Authority
JP
Japan
Prior art keywords
seq
amino acid
antibody
acid sequence
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2023505901A
Other languages
English (en)
Japanese (ja)
Inventor
ウェンツ ゴン，
イーウェイ トウ，
Original Assignee
レプ バイオファーマ カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レプ バイオファーマ カンパニー リミテッド filed Critical レプ バイオファーマ カンパニー リミテッド
Publication of JP2023540436A publication Critical patent/JP2023540436A/ja
Priority to JP2024187749A priority Critical patent/JP7846734B2/ja
Priority to JP2025194419A priority patent/JP2026015500A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023505901A 2020-07-28 2021-07-27 Ｐｄ－ｌ１およびｔｇｆ－βを標的とする二機能性分子 Withdrawn JP2023540436A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024187749A JP7846734B2 (ja) 2020-07-28 2024-10-24 Ｐｄ－ｌ１およびｔｇｆ－βを標的とする二機能性分子
JP2025194419A JP2026015500A (ja) 2020-07-28 2025-11-13 Ｐｄ－ｌ１およびｔｇｆ－βを標的とする二機能性分子

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/105286 2020-07-28
CN2020105286 2020-07-28
CNPCT/CN2021/098476 2021-06-04
CN2021098476 2021-06-04
PCT/CN2021/108643 WO2022022503A1 (en) 2020-07-28 2021-07-27 Bifunctional molecules targeting pd-l1 and tgf-beta

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024187749A Division JP7846734B2 (ja) 2020-07-28 2024-10-24 Ｐｄ－ｌ１およびｔｇｆ－βを標的とする二機能性分子

Publications (1)

Publication Number Publication Date
JP2023540436A true JP2023540436A (ja) 2023-09-25

Family

ID=80037607

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2023505901A Withdrawn JP2023540436A (ja) 2020-07-28 2021-07-27 Ｐｄ－ｌ１およびｔｇｆ－βを標的とする二機能性分子
JP2024187749A Active JP7846734B2 (ja) 2020-07-28 2024-10-24 Ｐｄ－ｌ１およびｔｇｆ－βを標的とする二機能性分子
JP2025194419A Pending JP2026015500A (ja) 2020-07-28 2025-11-13 Ｐｄ－ｌ１およびｔｇｆ－βを標的とする二機能性分子

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024187749A Active JP7846734B2 (ja) 2020-07-28 2024-10-24 Ｐｄ－ｌ１およびｔｇｆ－βを標的とする二機能性分子
JP2025194419A Pending JP2026015500A (ja) 2020-07-28 2025-11-13 Ｐｄ－ｌ１およびｔｇｆ－βを標的とする二機能性分子

Country Status (9)

Country Link
US (1) US20230287125A1 (https=)
EP (1) EP4188950A4 (https=)
JP (3) JP2023540436A (https=)
KR (1) KR20230050356A (https=)
CN (4) CN121319180A (https=)
AU (1) AU2021317376A1 (https=)
IL (1) IL299966A (https=)
PH (1) PH12023550193A1 (https=)
WO (1) WO2022022503A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026508210A (ja) * 2023-02-20 2026-03-10 中山康方生物医▲藥▼有限公司 ＴＧＦ－βＲＩＩ細胞外領域断片を含む融合タンパク質、その医薬組成物、およびその使用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018527949A (ja) * 2015-08-06 2018-09-27 ウーシー バイオロジクス（シャンハイ）カンパニー リミテッド 新規抗ｐｄ−ｌ１抗体
WO2018205985A1 (zh) * 2017-05-12 2018-11-15 江苏恒瑞医药股份有限公司 含有TGF-β受体的融合蛋白及其医药用途
WO2019113464A1 (en) * 2017-12-08 2019-06-13 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
JP2019516394A (ja) * 2016-03-23 2019-06-20 マブスペース バイオサイエンシズ （スーチョウ） カンパニー，リミテッド 新規抗ｐｄ−ｌ１抗体
JP2020504095A (ja) * 2016-12-08 2020-02-06 イーライ リリー アンド カンパニー 抗ＰＤ−Ｌ１抗体との組み合わせのための抗Ｔｉｍ−３抗体

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9676863B2 (en) * 2014-02-10 2017-06-13 Merck Patent Gmbh Targeted TGFβ inhibitors
EP3369745B1 (en) * 2016-08-04 2021-09-29 Innovent Biologics (Suzhou) Co., Ltd. Anti-pd-l1 nanobody and use thereof
CN109575140B (zh) * 2017-09-29 2021-02-23 北京比洋生物技术有限公司 靶向pd-1或pd-l1且靶向vegf家族的双靶向融合蛋白及其用途
EP3470429A1 (en) * 2017-10-10 2019-04-17 Numab Innovation AG Antibodies targeting pdl1 and methods of use thereof
CN109721657B (zh) * 2017-10-27 2021-11-02 北京比洋生物技术有限公司 阻断pd-1/pd-l1信号传导途径且活化t细胞的融合蛋白及其用途
WO2019185029A1 (en) * 2018-03-29 2019-10-03 I-Mab Anti-pd-l1 antibodies and uses thereof
BR112021003093A2 (pt) * 2018-08-22 2021-05-11 Merck Patent Gmbh tratamento de câncer de mama triplo negativo que visa a inibição de tgf-beta
US12559539B2 (en) * 2018-11-09 2026-02-24 Jiangsu Hengrui Medicine Co., Ltd. TGF-beta receptor fusion protein pharmaceutical composition and use thereof
US10851157B2 (en) * 2019-07-01 2020-12-01 Gensun Biopharma, Inc. Antagonists targeting the TGF-β pathway
US11028174B1 (en) * 2020-07-28 2021-06-08 Lepu Biopharma Co., Ltd. Bifunctional molecules targeting PD-L1 and TGF-β
CN112940134B (zh) * 2021-05-11 2021-09-03 正大天晴药业集团南京顺欣制药有限公司 针对PD-1和TGF-β的双功能蛋白

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018527949A (ja) * 2015-08-06 2018-09-27 ウーシー バイオロジクス（シャンハイ）カンパニー リミテッド 新規抗ｐｄ−ｌ１抗体
JP2019516394A (ja) * 2016-03-23 2019-06-20 マブスペース バイオサイエンシズ （スーチョウ） カンパニー，リミテッド 新規抗ｐｄ−ｌ１抗体
JP2020504095A (ja) * 2016-12-08 2020-02-06 イーライ リリー アンド カンパニー 抗ＰＤ−Ｌ１抗体との組み合わせのための抗Ｔｉｍ−３抗体
WO2018205985A1 (zh) * 2017-05-12 2018-11-15 江苏恒瑞医药股份有限公司 含有TGF-β受体的融合蛋白及其医药用途
WO2019113464A1 (en) * 2017-12-08 2019-06-13 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof

Also Published As

Publication number Publication date
CN119462927B (zh) 2025-07-29
EP4188950A1 (en) 2023-06-07
PH12023550193A1 (en) 2024-06-24
WO2022022503A1 (en) 2022-02-03
JP2025010203A (ja) 2025-01-20
IL299966A (en) 2023-03-01
KR20230050356A (ko) 2023-04-14
CN116348493B (zh) 2025-10-17
CN119409832B (zh) 2025-08-01
EP4188950A4 (en) 2025-01-22
CN121319180A (zh) 2026-01-13
US20230287125A1 (en) 2023-09-14
JP2026015500A (ja) 2026-01-29
CN116348493A (zh) 2023-06-27
JP7846734B2 (ja) 2026-04-15
CN119462927A (zh) 2025-02-18
CN119409832A (zh) 2025-02-11
AU2021317376A1 (en) 2023-02-23

Similar Documents

Publication Publication Date Title
US11634490B2 (en) Blocking antibodies against CD47 and methods of use thereof
JP2025135612A (ja) 抗クローディン－１８．２と抗４－１ｂｂとの二重特異性抗体およびその使用
US20230012428A1 (en) Bifunctional fusion protein and pharmaceutical use thereof
KR102608723B1 (ko) 항―ｐｄ－１ 항체 및 그의 용도
CN116745317B (zh) 抗tigit抗体及其用途
US12570742B2 (en) Anti-SIRPα monoclonal antibodies and uses thereof
WO2018219327A1 (zh) 抗cd40抗体、其抗原结合片段及其医药用途
US11028174B1 (en) Bifunctional molecules targeting PD-L1 and TGF-β
BR112020021280A2 (pt) anticorpos anti-dll3 e usos dos mesmos
WO2022171100A1 (zh) Gpc3人源化抗体及其应用
JP2023524102A (ja) Ａｂｃｂ５に特異的な抗体およびその使用
CN109988240A (zh) 抗gpc-3抗体及其用途
KR20220089688A (ko) 항-pd-1 항체 및 이의 용도
KR20200088810A (ko) 항―ｏｘ４０ 항체 및 그의 용도
WO2022166876A1 (zh) 特异性识别磷脂酰肌醇蛋白聚糖3的单克隆抗体及其应用
US20240209093A1 (en) Single domain pd-l1 antibodies
JP2026015500A (ja) Ｐｄ－ｌ１およびｔｇｆ－βを標的とする二機能性分子
WO2022110922A1 (zh) 抗SIRPα抗体或其抗原结合片段及应用
CN116333125A (zh) 结合死亡受体4和死亡受体5的抗体
US12247081B2 (en) CEACAM5-dependent 4-1BB-agonistic bispecific antibodies
HK40088153A (zh) 靶向PD-L1和TGF-β的双功能分子
HK40094973A (zh) 抗SIRPα单克隆抗体及其用途
HK40098542A (zh) 抗SIRPα单克隆抗体及其用途
HK40126806A (zh) 抗slc34a2单克隆抗体及其用途
TW202504921A (zh) Ceacam5依賴性4-1bb促效性雙特異性抗體

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230630

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240524

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240823

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20241108